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Abstract 
Purpose: To evaluate the antitrypanosomal activity of Malva sylvestris (MS) extract in a Trypanosoma 
brucei brucei-infected mouse model of sleeping sickness.  
Methods: Sleeping sickness was induced by the intraperitoneal injection of Trypanosoma brucei brucei-
infected blood in mice. Confirmation of parasitaemia was performed by estimating the parasite count in 
the plasma on the 12th day after inoculation. All the mice were divided into five groups: control group 
that received neither infection nor treatment; negative control that was infected with the parasite but did 
not receive treatment; MS-treated group that receive MS extract (250 and 500 mg/kg, ip) and standard 
(STD) group that received levamisole (7.5 mg/kg, ip) for 7 days after the development of parasitaemia. 
A further parasite count was performed in the blood and cerebrospinal fluid (CSF) after the treatment 
period. Humoral antibody response, delayed hypersensitivity reaction, and mobilization of leucocytes 
were determined after the treatment period in SRBC-sensitized mice.  
Results: The results indicate that treatment with MS significantly decreased body weight and parasite 
count in the blood and CSF of mice with Trypanosoma brucei brucei-induced sleeping sickness 
compared with that in the negative control group. There was a significant increase in paw swelling and 
decrease in secondary antibody in the MS-treated group compared with that in the negative control 
group. However, treatment with MS extract also enhanced the mobilization of the total leucocyte count 
compared with that in the negative control group.  
Conclusion: The results demonstrate the anti-trypanosomal activity of Malva sylvestris extract via 
immunomodulation in a Trypanosoma brucei brucei-infected mouse model of sleeping sickness. 
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Sleeping sickness is a disease that occurs 
because of infection by protozoa (genus: 
Trypanosoma) and is commonly known as 
epidemic encephalitis or human African 
trypanosomiasis [1]. A report of WHO has 
revealed that approximately 60 million people of 
African countries are at a risk to become 
infected with sleeping sickness, which is found 
to be fatal if left untreated [2]. The literature 
suggests that sleeping sickness is transmitted 
through the tsetse fly and is commonly known 
as Trypanosoma brucei brucei [3]. This disease 
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occurs in two stages. Stage 1 is commonly 
known as hemolymphatic stage 1in which the 
parasite attacks the peripheral organs and 
proliferate in the lymph and blood. Stage 2 is 
called meningoencephalitic stage 2 in which the 
infection reaches the CNS by crossing the blood 
brain barrier [4,5]. In the second stage, the 
disease affects the neurological functions, 
including sleeping, and it causes mortality if it 
remains untreated. Disease caused due to 
microbial agent fundamentally protected by 
immune system. Activation of the immune 
system stimulates the release of mediators of 
inflammation such as chemokines and 
cytokines, thereby managing the disease [6]. 
 
However, in this modern era of medicine, it 
remains challenging to treat such a condition. 
Treatment of this disease requires the 
administration of a parental preparation for a 
longer duration with less efficacy, and, most of 
the time, it is not affordable for patients. Thus, 
an alternative therapy is required to manage 
this disease. Malva sylvestris L. (Malvacea) is 
traditionally used as medicine in China [7]. MS 
was reported to possess anti-inflammatory, 
antioxidant, bacteriostatic, antinociceptive and 
anticholinesterase activity [8,9]. Phytochemical 
investigation revealed that MS herbs contain 
several biologically active chemical components 
such as essential oils, sesquiterpenes, 
leucoanthocyanidines, anthocyanidines, 
coumarins and anthocyanins [10]. Coumarins 
and anthocyanins were reported to protect 
neurodegeneration in cerebral ischaemia [11]. 
Thus, we assessed the antitrypanosomal effects 
of Malva sylvestris extract on a Trypanosoma 






Male albino mice of 25 to 50 g body weight were 
used in the given investigation. All the mice were 
housed under a controlled condition specified as 
per the guidelines. All the experiments used in 
the given study are approved by institutional 
animal ethical committee of Hubei Provincial 
Hospital of TCM, China (no. HPH/IAEC/2016/02) 
and the study followed the guidelines of 
Association for the Assessment and 
Accreditation of Laboratory Animal Care 
International (AAALAC) for experimentation and 
animal use [12]. 
 
Preparation of extract 
 
The whole plant of Malva sylvestris was collected 
and authenticated from Dr. Wu Wang of 
Jianghan University, China. The complete plant 
was air dried after washing it. The dried plants 
were cut into small pieces and later ground into a 
coarse powder using a grinder. This powder was 
kept in 95 % methanol in a bottle for 7 days for 
the maceration. The extract was filtered, and the 
filtrate was dried using a rotary evaporator. The 




The Trypanosome strain (Trypanosoma brucei 
brucei) was procured from the School of 
Medicine, Jianghan University, China. It was 
maintained at the department by serial passage 
in the animals. However, the identification of 
Trypanosoma brucei brucei was performed by 




All the mice were separated into five different 
groups such as the control group that received 
neither infection nor treatment, a negative control 
group that was infected with the parasite but did 
not receive treatment, an MS-treated group that 
received the MS extract (250 and 500 mg/kg, ip) 
and a STD group that received levamisole (7.5 
mg/kg, ip) for 7 days after the development of 
parasitaemia. 
 
Infected mice were used to collect the blood by 
cardiac puncture, followed by dilution in saline 
solution. This blood was then inoculated into all 
the groups of mice by ip injection containing 
approximately 1 × 106 Trypanosome cells/ml. All 
the mice were kept for 12 days for the 
development of parasitaemia. All the animals 
were treated with the MS extract for 7 days, and 
microscopic examination was performed at an 
interval of every 2 days for the estimation of 
parasitaemia. 
 
Determination of the body weight and 
parasite count  
 
The body weight and parasite count in the 
blood of all the infected mice were estimated 
on every alternate day after the inoculation 
of the parasite. However, the parasite count 
was estimated in the CSF at 0 and 7 days of 
infection. The animals were anesthetized by 
the injection of chloral hydrate (400 mg / kg), 
and the CSF was collected by making a 
puncture at the cisterna magna using a 
stereotaxic frame. The CSF was collected by 
inserting syringes in it. The parasite counting 
was performed using a microscope as 
described previously. 
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Preparation of sheep red blood cells (SRBCs) 
 
In this study, blood collected from sheep 
(SRBCs) was used as an antigen. Red blood 
cells were separated from the collected blood, 
followed by washing with phosphate-buffered 
saline (pH 7.2) three times by centrifugation at 
2000 × for 10 min. After washing, the SRBCs 
obtained were subjected to serological tests 
using a 2 % suspension of SRBCs in PBS and 
prepared for immunization using a 10 % 
suspension of the cells. 
 
Delayed hypersensitivity reaction test 
 
SRBC was used to induce delayed 
hypersensitivity reaction in the mice. Thirty mice 
were separated into five different groups as 
described in the above section of the study. On 
day 0, infected mouse SRBCs (0.2 mL, 1 × 109) 
was injected into the planter region of the right 
hind foot pad for sensitization. However, in the 
left hind pad, another injection of SRBCs was 
administered subcutaneously on day six. 
However, the thickness of left foot pad was 
estimated by a vernier calliper before and after 
24 h of the challenge. 
 
Humoral antibody response 
 
Blood was withdrawn from all the animals and 
was centrifuged at 10,000 rpm. Hemagglutination 
technique was used for the estimation of the 
antibody titre. In a micro titre 96-well plate, serum 
was diluted using normal saline up to two folds; 
later, 1 % of SRBCs was added to each dilution. 
Thereafter, the plates were incubated for 60 min 
at 37 °C, and then it was observed for 
hemagglutination. 
 
Evaluation of the mobilization of leucocytes  
 
The method reported by Ribeiro et al was used 
to estimate the mobilization of leucocytes in this 
study. At the end of the treatment period, all the 
animals were sacrificed 4 h after the ip injection 
of 0.5 mL of agar solution. The peritoneal region 
of all the mice was washed with phosphate buffer 
solution containing 10 % EDTA (0.5 mL). Next, a 
haemocytometer was used to estimate the total 
leucocyte count in the peritoneal fluid, and a 
Giemsa-stained perfusate smear was observed 
microscopically for the estimation of the 
differential cell count. 
 
Statistical analysis  
 
All the data were represented as means ± 
standard deviation (n = 10). All the results were 
analysed statistically by one-way analysis of 
variance and Dunnett’s post-hoc test (GraphPad 
Prism 6.1., La Jolla, CA, USA). P < 0.05 was 




Effect of Malva sylvestris extract on body 
weight 
 
Effect of Malva sylvestris extract on the body 
weight of mice with Trypanosoma brucei brucei-
induced sleeping sickness was seen at 0, 12 and 
19 days of the protocol (Figure 1). It was 
observed that the body weight of T. brucei 
brucei-infected mice was significantly (p < 0.05, p 
< 0.01) decreased on the 12th day (Without drug 
treatment) compared with the control group. This 
fall in the body weight continued in the negative 
control group up to the 19th day of the protocol.  
 
 
Figure 1: Effect of Malva sylvestris extracton body weight of sleeping sickness mice model. Values are mean ± 
SD; * p < 0.05; ** p < 0.01 compared with control group; ## p < 0.01 compared with negative control group 
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However, treatment with MS and STD 
significantly (p < 0.01) improved the weight of 
Trypanosoma brucei brucei-induced sleeping 
sickness mice. 
 
Effect of Malva sylvestris extract on the 
parasite count 
 
The effect of MS on parasite count in the blood 
and CSF of the sleeping sickness mouse model 
is shown in Figure 2. There was an increase in 
the count of parasites in the blood and CSF of 
mice after the 12th day of the protocol (i.e. period 
of induction of parasitaemia), confirming the 
induction of parasitaemia. However, treatment 
with MS and STD significantly (p < 0.01) 
decreased the count of parasites in the blood 
and CSF of the sleeping sickness mouse model 




Effect of Malva sylvestris extract on delayed 
hypersensitivity reaction 
 
The effect of Malva sylvestris on delayed 
hypersensitivity reaction in the sleeping sickness 
mouse model was estimated by determining the 
paw swelling (Table 1). It was observed that 
treatment with MS 250 and 500 mg / kg 
significantly reduced the paw swelling. Moreover, 
it also decreased the inhibition. 
 
Effect of Malva sylvestris extract on the 
humoral antibody response 
 
The effect of MS on the humoral antibody 
response is shown in Table 2. There was a 
significant increase in the SRBC secondary 
antibody production in the MS- and STD-treated 
groups compared with that in the control group. It 
was observed that the production of secondary 
antibody was enhanced in the MS-treated group 
in a dose-dependent manner. 
 
        
(A)       (B) 
Figure 2: Effect of Malva sylvestris extract on the parasitaemia of sleeping sickness mice model (A) parasite 
count in blood (B) parasite count in CSF. Values are mean ± SD;* p < 0.05, ** p < 0.01 compared with control 
group, ##p < 0.01 compared with negative control group 
 
Table 1: Effect of Malva sylvestris extract on delayed hypersensitivity reaction in sleeping sickness mice model 
 
Group Paw swelling (mm) Inhibition (%) 
Control 1.09±0.07 -- 
MS (250 mg/kg) 1.21±0.05# -17.52±1.9 
MS (500 mg/kg) 1.83±0.06# -23.86±2.2 
Standard* 1.08±0.09 00.00 
Note: Values are mean ± SD; # p < 0.05, ## p < 0.01 compared with control group; *levamisole 7.5 mg/kg 
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Table 2: Effect of Malva sylvestris on primary and secondary response (log102) in sleeping sickness mice model 
 




Control 1.32±0.37 1.57±0.32 
MS (250 mg/kg) 3.53±0.05 3.15±0.87## 
MS (500 mg/kg) 4.83±0.06 8.52±1.31## 
STD (levamisole 7.5 mg/kg) 2.95±0.69 2.97±0.46## 
Note: Values are means ± SD; # p < 0.05, ## p < 0.01 compared with control group 
 














Control 957±89 184±8.2 742±52 16.5±1.1 17.9±1.2 6.3±0.8 
MS (250 mg/kg) 1418±215## 259±11.5## 810±71# 1.2±0.15## 10.2±1.5## 4.1±0.3## 




1130±140## 277±17.3## 879±48## 1.6±0.3## 1.6±0.5## 00±00 
Note: Values are mean ± SD; # p < 0.05, ## p < 0.01 compared with control group 
 
Effect of Malva sylvestris extract on the 
mobilization of leucocytes 
 
The effect of MS on the mobilization of 
leucocytes is shown in Table 3. The mobilization 
of the total leucocyte (TLC), neutrophil and 
lymphocyte count was significantly enhanced in 
the MS-and STD-treated group compared with 
that in the control group. Moreover, the basophil, 
monocyte and eosinophil counts were decreased 
in the MS- and STD-treated groups compared 




Protozoal infection of Trypanosoma brucei brucei 
causes epidemic encephalitis [13]. The literature 
suggested that infection of Trypanosoma brucei 
brucei caused fatal if it remains untreated [2]. 
However, effective management of sleeping 
sickness remains a challenge, and several 
molecules from herbal sources have 
demonstrated a therapeutic potential for the 
management of the disease [14,15]. Thus, this 
study evaluated the anti-trypanosomal effects of 
Malva sylvestris extract on a Trypanosoma 
brucei brucei-infected mouse model of sleeping 
sickness. The study also postulated the possible 
mechanism of its action. 
 
In this study, MS treatment significantly led to the 
recovery of mice body weight of Trypanosoma 
brucei brucei-induced sleeping sickness 
compared with that in negative control group. 
The literature suggests that the enhanced 
parasite count confirms the induction of 
parasitaemia in all the Trypanosoma brucei 
brucei-induced sleeping sickness mice [16]. 
However, it also decreased the parasite count in 
the blood and CSF of Trypanosoma brucei 
brucei-induced sleeping sickness mice compared 
with that in negative control group.  
 
Protection of the body from pathogens is the 
fundamental function of the immune system. 
Thus, the drugs that can stimulate the immune 
system are effectively used for the management 
of this disease [17]. In this study, the mechanism 
of anti-trypanosomal activity of MS is believed to 
be due to immunomodulatory activity. Infection of 
intracellular pathogens is majorly influenced by 
delayed hypersensitivity reaction. Delayed 
hypersensitivity represents cellular immunity that 
activates the production of cytokines, thereby 
deactivating the antigen [18]. However, treatment 
with MS significantly enhanced the paw swelling, 
indicating that the extract may have anti-
inflammatory properties. However, the results of 
the mobilization of leukocytes also suggest that 
MS significantly enhances TLC, neutrophil and 
lymphocyte counts in the blood. These results 




The results confirm the anti-trypanosomal activity 
of Malva sylvestris extract by immunomodulation. 
The extract of Malva sylvestris has potentials for 
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